Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorStagg, Helen R
dc.contributor.authorThompson, Jennifer A
dc.contributor.authorLipman, Marc C I
dc.contributor.authorSloan, Derek J
dc.contributor.authorFlook, Mary
dc.contributor.authorFielding, Katherine L
dc.date.accessioned2024-01-15T00:35:22Z
dc.date.available2024-01-15T00:35:22Z
dc.date.issued2023-01-15
dc.identifier280978878
dc.identifier82132373-5a59-44c1-9713-8e9c437bea73
dc.identifier000912325900015
dc.identifier85146364763
dc.identifier.citationStagg , H R , Thompson , J A , Lipman , M C I , Sloan , D J , Flook , M & Fielding , K L 2023 , ' Forgiveness is the attribute of the strong : nonadherence and regimen-shortening in drug-sensitive TB ' , American Journal of Respiratory and Critical Care Medicine , vol. 207 , no. 2 , pp. 193-205 . https://doi.org/10.1164/rccm.202201-0144ocen
dc.identifier.issn1073-449X
dc.identifier.otherJisc: 544377
dc.identifier.otherORCID: /0000-0002-7888-5449/work/129147929
dc.identifier.urihttps://hdl.handle.net/10023/29008
dc.descriptionFunding: HRS and MF are supported by the UK Medical Research Council (MRC) [MR/R008345/1]. HRS and MCIL are supported through the National Institute for Health Research (NIHR) Health Technology Assessment Programme, UK [16/88/06]. JAT is jointly funded by the UK MRC and the UK Foreign, Commonwealth and Development Office (FCDO) under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union. Grant Ref: MR/R010161/1. KLF is partly funded by the UK MRC and the UK FCDO under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union.en
dc.description.abstractRationale : ‘Forgiveness’ charts the ability of a drug or regimen to withstand non-adherence without negative clinical consequences. Objectives : We aimed to determine the influence of regimen length, regimen drugs and dosing, and when during treatment non-adherence occurs on the forgiveness of anti-tuberculosis regimens. Methods : Using data from three randomised controlled trials comparing experimental four-month regimens for drug-sensitive tuberculosis with the standard six-month regimen, we used generalised linear models to examine how the risk of a negative composite outcome changed as dose-taking decreased. The percentage of doses taken and absolute number of doses missed were calculated, during the intensive and continuation phases of treatment, and overall. A mediation analysis was undertaken to determine how much of the association between intensive phase dose-taking and the negative composite outcome was mediated through continuation phase dose-taking. Measurements and Main Results : Forgiveness of the four-month and six-month regimens did not differ for any treatment period. Importantly, four-month regimens were no less forgiving of small numbers of absolute missed doses than the six-month regimen (e.g. for 3-7 missed doses versus no missed doses (baseline), six-month regimen adjusted risk ratio 1.65 (95% confidence interval 0.80-3.41) and four-month regimens 1.80 (1.33-2.45)). No four-month regimen was conclusively more forgiving than another. We found evidence of mediation by continuation phase dose-taking on the intensive phase dose-taking and negative composite outcome relationship. Conclusions : With the current appetite for, and progress towards, shorter drug-sensitive tuberculosis regimens worldwide, we offer reassurance that shorter regimens are not necessarily less forgiving of non-adherence. Given the importance of continuation phase adherence, patient support during this period should not be neglected.
dc.format.extent13
dc.format.extent2921277
dc.language.isoeng
dc.relation.ispartofAmerican Journal of Respiratory and Critical Care Medicineen
dc.subjectTuberculosisen
dc.subjectForgivenessen
dc.subjectAdherenceen
dc.subjectNon-adherenceen
dc.subjectTreatmenten
dc.subjectRM Therapeutics. Pharmacologyen
dc.subject3rd-DASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectACen
dc.subjectMCCen
dc.subject.lccRMen
dc.titleForgiveness is the attribute of the strong : nonadherence and regimen-shortening in drug-sensitive TBen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.contributor.institutionUniversity of St Andrews. Infection and Global Health Divisionen
dc.identifier.doi10.1164/rccm.202201-0144oc
dc.description.statusPeer revieweden
dc.date.embargoedUntil2024-01-15


This item appears in the following Collection(s)

Show simple item record